Global Diabetes Injection Pen Market Trends, Analysis, Growth, and Forecast: 2018 to 2027

MarketResearch.biz delivers in-depth insights on the global diabetes injection pen market in its upcoming report titled, “Global Diabetes Injection Pen Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global diabetes injection pen market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global diabetes injection pen market report has been segmented on the basis of product type, usage, distribution channel, and region.

Request Covid - 19 Impact

Injection pens injects insulin in the body which provides various advantages over the traditional vial-and-syringe method. Furthermore, it is easy to use and provides accuracy in delivering small dose of insulin. The small & thin needle sizes reduce fear and pain and thus has greater social acceptability. Diabetes injection pens are compact size and portable.

Increasing prevalence of diabetes globally is expected to drive the global diabetes injection pen market over the forecast period. According to American Diabetes Association, in 2015, 30.3 million people in US had diabetes which is 9.4% of the population. In addition, increasing preference of diabetes injection pen over the traditional vial-and-syringes due to the rising incidence of needle stick injuries is expected to fuel the global diabetes injection pen market over the forecast period. Increasing number of product approvals for injection pen by health authorities for treatment of diabetes is expected propel the growth of global diabetes injection pen market over the forecast period.

However, preference of other alternative drug delivery modes such insulin patches, tablets is a major factors restraining the growth of global diabetes injection pen market over the forecast period.

North America market dominates the global diabetes injection pen market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to the increasing number of approvals and subsequent launch of new products, increasing number of cases of diabetes, and continuous development of advanced injection pens by manufacturers in the region. Europe accounts for second-largest revenue share contribution to the global diabetes injection pen market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years. This is attributed owing to rapidly growing geriatric population, improving healthcare infrastructure, and rising awareness among the patients in the region.

Global diabetes injection pen market segmentation, by product type:

• Insulin Pens
• Pen Needles

 Global diabetes injection pen market segmentation, by usage:

• Reusable Injection Pen
• Disposable Injection Pen

Global diabetes injection pen market segmentation, by distribution channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Medical Stores
• Diabetes Clinics

 Global diabetes injection pen market segmentation, by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Novo Nordisk A/S
• Sanofi SA
• Eli Lilly and Company
• Merck & Company, Inc.
• Astrazeneca plc
• Jiangsu Delfu medical device Co., Ltd.
• Becton, Dickinson and Company
• Hoffmann-La Roche AG
• Biocon
• Wockhardt Ltd.